![Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/04baaeea-8e96-4eb9-b058-cd3c11aacb89/gr2_lrg.jpg)
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The
![A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/4c56dec5-310c-4e24-ab78-fbf95f7c8023/gr1.jpg)
A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine
![Event-free survival and overall survival (A) Event-free survival for... | Download Scientific Diagram Event-free survival and overall survival (A) Event-free survival for... | Download Scientific Diagram](https://www.researchgate.net/profile/Susan-Cohn-2/publication/253332767/figure/fig1/AS:616365463461888@1523964386076/Event-free-survival-and-overall-survival-A-Event-free-survival-for-intention-to-treat.png)
Event-free survival and overall survival (A) Event-free survival for... | Download Scientific Diagram
![Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic](https://d3i71xaburhd42.cloudfront.net/2aa8254fae649d2ab35d92abb79d94fa9d17f39e/4-Figure1-1.png)
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
![Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) - Journal of Thoracic Oncology Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/49cd6e8f-4319-457e-af00-4dbbab967dfb/gr1.jpg)
Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) - Journal of Thoracic Oncology
![Cancers | Free Full-Text | Prognostic Clinical and Biologic Features for Overall Survival after Relapse in Childhood Medulloblastoma | HTML Cancers | Free Full-Text | Prognostic Clinical and Biologic Features for Overall Survival after Relapse in Childhood Medulloblastoma | HTML](https://www.mdpi.com/cancers/cancers-13-00053/article_deploy/html/images/cancers-13-00053-g002.png)
Cancers | Free Full-Text | Prognostic Clinical and Biologic Features for Overall Survival after Relapse in Childhood Medulloblastoma | HTML
![Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low–middle-income country | SpringerLink Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low–middle-income country | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00277-019-03661-7/MediaObjects/277_2019_3661_Fig3_HTML.png)
Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low–middle-income country | SpringerLink
![Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology](https://www.jcancer.org/v10/p3717/jcav10p3717g002.jpg)
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
![Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma | SpringerLink Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00277-020-04195-z/MediaObjects/277_2020_4195_Fig4_HTML.png)
Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma | SpringerLink
![Improved Event-Free Survival and Higher Incidence of Early Fever Associated with Mismatches at HLA-DRB1 after Nonmyeloablative HLA-Haploidentical Transplantation - Biology of Blood and Marrow Transplantation Improved Event-Free Survival and Higher Incidence of Early Fever Associated with Mismatches at HLA-DRB1 after Nonmyeloablative HLA-Haploidentical Transplantation - Biology of Blood and Marrow Transplantation](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/7b390ded-6c92-4578-8079-4e858709eaf2/ybbmt54468-fig-0001_lrg.jpg)
Improved Event-Free Survival and Higher Incidence of Early Fever Associated with Mismatches at HLA-DRB1 after Nonmyeloablative HLA-Haploidentical Transplantation - Biology of Blood and Marrow Transplantation
![Wilms tumour event-free and overall survival in Southern and Eastern Europe: Pooled analyses of clinical data from four childhood cancer registries (1999–2017) - European Journal of Cancer Wilms tumour event-free and overall survival in Southern and Eastern Europe: Pooled analyses of clinical data from four childhood cancer registries (1999–2017) - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/71237f19-809d-4fa5-8f44-dd5e4a6b1c0d/gr1.jpg)
Wilms tumour event-free and overall survival in Southern and Eastern Europe: Pooled analyses of clinical data from four childhood cancer registries (1999–2017) - European Journal of Cancer
![Relationship between presarcopenia and event occurrence in patients with primary hepatocellular carcinoma | Scientific Reports Relationship between presarcopenia and event occurrence in patients with primary hepatocellular carcinoma | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-67147-7/MediaObjects/41598_2020_67147_Fig1_HTML.png)
Relationship between presarcopenia and event occurrence in patients with primary hepatocellular carcinoma | Scientific Reports
![Kaplan Meier plots, showing the difference in overall survival, event... | Download Scientific Diagram Kaplan Meier plots, showing the difference in overall survival, event... | Download Scientific Diagram](https://www.researchgate.net/publication/339438552/figure/fig1/AS:862080768962563@1582547480495/Kaplan-Meier-plots-showing-the-difference-in-overall-survival-event-free-survival-and.png)
Kaplan Meier plots, showing the difference in overall survival, event... | Download Scientific Diagram
![Acute myeloid leukemia: survival analysis of patients at a university hospital of Paraná | Hematology, Transfusion and Cell Therapy Acute myeloid leukemia: survival analysis of patients at a university hospital of Paraná | Hematology, Transfusion and Cell Therapy](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/S1516848414001455:gr5.jpeg?xkr=ue/ImdikoIMrsJoerZ+w92xcqUtYYCc6yiYRjTD2AR1aFJOKb7qLd+WBf18Ptk/O8dVG5SMqADZji5skBxdmL83IXxo36SddaR63DsSq89mcTB3Hj+ztPQGA6zqULHnBHpT4s9P3G9ZiXVHfJK3hkMt6mGddu7dsrxAXvHUh2DAVXS65CzzQbSvmIJw+LHH0O4cvudJZ1sLq1lL32NJzmn7aCG/A8lqqCCpYSf7gw6Yqtabyu1B9BQu3aUSQbWle/cVVQFMzbA7D0xvmQlEfSn1+4DQxS/Nh1yR4KMO+RokNoQNIIr1UbZEoIivRQdSk)
Acute myeloid leukemia: survival analysis of patients at a university hospital of Paraná | Hematology, Transfusion and Cell Therapy
![Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma](https://www.frontiersin.org/files/Articles/835389/fonc-12-835389-HTML/image_m/fonc-12-835389-g002.jpg)
Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
![Kaplan-Meier plot of event-free survival (EFS) and overall survival... | Download Scientific Diagram Kaplan-Meier plot of event-free survival (EFS) and overall survival... | Download Scientific Diagram](https://www.researchgate.net/publication/312303406/figure/fig1/AS:625531582177282@1526149759970/Kaplan-Meier-plot-of-event-free-survival-EFS-and-overall-survival-OS-A-EFS-in-all.png)
Kaplan-Meier plot of event-free survival (EFS) and overall survival... | Download Scientific Diagram
![BrighTNess Neoadjuvant Carboplatin Improves Event-Free Survival in Triple-Negative Breast Cancer - The ASCO Post BrighTNess Neoadjuvant Carboplatin Improves Event-Free Survival in Triple-Negative Breast Cancer - The ASCO Post](https://ascopost.com/media/14018436/29-table1.jpg)
BrighTNess Neoadjuvant Carboplatin Improves Event-Free Survival in Triple-Negative Breast Cancer - The ASCO Post
![Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation | Journal of Clinical Oncology Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2020/jco.2020.38.issue-26/jco.19.03114/20200825/images/large/jco.19.03114t3.jpeg)
Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation | Journal of Clinical Oncology
![Myeloid sarcoma is associated with superior event‐free survival and overall survival compared with acute myeloid leukemia - Tsimberidou - 2008 - Cancer - Wiley Online Library Myeloid sarcoma is associated with superior event‐free survival and overall survival compared with acute myeloid leukemia - Tsimberidou - 2008 - Cancer - Wiley Online Library](https://acsjournals.onlinelibrary.wiley.com/cms/asset/584fbe4d-53b0-4375-9b27-40dea8af33a5/mfig002.jpg)
Myeloid sarcoma is associated with superior event‐free survival and overall survival compared with acute myeloid leukemia - Tsimberidou - 2008 - Cancer - Wiley Online Library
![Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast. - ppt download Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast. - ppt download](https://images.slideplayer.com/30/9505354/slides/slide_4.jpg)
Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast. - ppt download
![Medical Science Monitor | Prognostic Significance of Clinicopathological Factors Influencing Overall Survival and Event-Free Survival of Patients with Cervical Cancer: A Systematic Review and Meta-Analysis - Article abstract #934588 Medical Science Monitor | Prognostic Significance of Clinicopathological Factors Influencing Overall Survival and Event-Free Survival of Patients with Cervical Cancer: A Systematic Review and Meta-Analysis - Article abstract #934588](https://jours.isi-science.com/imageXml.php?i=t2-medscimonit-28-e934588.jpg&idArt=934588&w=1000)
Medical Science Monitor | Prognostic Significance of Clinicopathological Factors Influencing Overall Survival and Event-Free Survival of Patients with Cervical Cancer: A Systematic Review and Meta-Analysis - Article abstract #934588
Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor | Haematologica
![Cancers | Free Full-Text | Prognostic Clinical and Biologic Features for Overall Survival after Relapse in Childhood Medulloblastoma | HTML Cancers | Free Full-Text | Prognostic Clinical and Biologic Features for Overall Survival after Relapse in Childhood Medulloblastoma | HTML](https://www.mdpi.com/cancers/cancers-13-00053/article_deploy/html/images/cancers-13-00053-g001.png)
Cancers | Free Full-Text | Prognostic Clinical and Biologic Features for Overall Survival after Relapse in Childhood Medulloblastoma | HTML
![Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial - Annals of Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial - Annals of](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/655713b2-4bf3-40b4-bce2-c931675e0982/gr2.jpg)